Conclusion:
Even though previous studies suggested favorable outcome for COVID-19 infection among patients with hemoglobinopathies. SCD remains at risk of acute deterioration even in the absence of any COVID-19 characteristic symptoms. Thus, close monitoring is necessary. ACS was mentioned before as a presentation of COVID-19 infection in those patients, yet acute hemolysis crisis should also be in mind. Offering RBCs exchange and admitting patients to the ICU until they are stable plays a role in improving prognosis and the earlier this is done the better the outcome. We believe that more studies are needed to form a clear guideline regarding RBCs exchange role and time of administration and the role of HU compliance on the course of infection.